WMWiparat Manuyakorn

Wiparat Manuyakorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wiparat Manuyakorn has a total of 194 co-authors. Here are the top co-authors by number of shared publications:

  • Wasu Kamchaisatian

    Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    25 shared publications
  • Wanlapa Jotikasthira

    Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

    17 shared publications
  • Suwat Benjaponpitak

    Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok, Thailand

    15 shared publications
  • Potjanee Kiewngam

    Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

    14 shared publications
  • Cherapat Sasisakulporn

    Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University

    12 shared publications
  • Watcharoot Kanchongkittiphon

    Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

    10 shared publications

Latest Publications

  • Open Access

    Impact of particulate matter 2.5 exposure on severity of pediatric chronic rhinitis: A prospective cohort study

    by Rinrada Naka, Ratchaneewan Sinitkul, Ussanai Nithirochananont, Watcharoot Kanchongkittiphon, Potjanee Kiewngam, Wanlapa Jotikasthira, Adithep Sawatchai, Chaiyawat Suppasilp, Wiparat Manuyakorn

    Background: Particulate matter with a diameter of ≤2.5 micrometers (PM 2.5 ) is associated with respiratory and allergic diseases. However, the longitudinal impact on pediatric rhinitis control remains limited. Objectives: To determine the association between PM 2.5 exposure and symptom control in pediatric patients with chronic rhinitis. Methods: This prospective longitudinal study (July 2024–August 2025) followed children with chronic rhinitis in the Bangkok Metropolitan Region. Rhinitis symptom severity was assessed weekly using a visual analog scale (VAS), with covariates such as medication use and concurrent respiratory infections. A 1‐week average PM 2.5 concentration preceding VAS assessment (via Inverse Distance Weighting interpolation) was estimated. Associations between PM 2.5 exposure and VAS were analyzed using multivariable mixed‐effects and fixed‐effects linear regression models. Additional analyses were stratified by aeroallergen sensitization status (allergic rhinitis versus nonallergic rhinitis). Results: Among 146 children followed for a median of 52 weeks, higher PM 2.5 exposure (per 10 μg/m 3 ) was consistently associated with increased VAS ( β coefficient; 95% confidence interval = 0.260; 0.215–0.306, p < .001). Wet season, concurrent respiratory infections, and medication use were also associated with increased VAS. These associations were observed in both allergic rhinitis and nonallergic rhinitis. Conclusion: Higher short‐term ambient PM 2.5 exposure was associated with greater rhinitis symptom severity in children with chronic rhinitis. These findings support consideration of ambient air pollution as an environmental factor in pediatric rhinitis management. image

  • Open Access

    Three Decades of Outcomes in Pediatric Inborn Errors of Immunity in a Middle-Income Setting: Survival by IUIS Class and the Role of HSCT

    by Chanunchida Watcharaporn, Usanarat Anurathapan, Suradej Hongeng, Samart Pakakasama, Wasu Kamchaisatian, Watcharoot Kanchongkittiphon, Wiparat Manuyakorn

    Inborn errors of immunity (IEI) comprise a heterogeneous group of inherited disorders associated with substantial morbidity and mortality, yet long-term outcome data from middle-income countries remain limited. We conducted a retrospective cohort study of 123 children diagnosed with IEI at a tertiary referral center in Thailand between 1991 and 2022 to characterize clinical features, treatment, and survival. Patients were retrospectively classified according to the 2022 International Union of Immunological Societies classification. Kaplan–Meier and Cox proportional hazards analyses were performed to evaluate survival and factors associated with mortality. Predominantly antibody deficiencies were the most common IEI category (40.7%), whereas severe combined immunodeficiency was the most frequent individual diagnosis. Genetic confirmation was obtained in 46.3% of patients, and 19 (15.4%) underwent hematopoietic stem cell transplantation (HSCT). Overall mortality was 31.7%, with infection remaining the leading cause of death. Survival differed substantially across IEI classes, with the poorest outcomes observed in combined immunodeficiencies and the most favorable survival in predominantly antibody deficiencies. Among patients with severe transplant-eligible IEI, exploratory analyses demonstrated improved survival following HSCT. In multivariable Cox analysis, both haploidentical HSCT (adjusted hazard ratio [aHR] 0.10, 95% confidence interval [CI] 0.03–0.33) and matched related donor HSCT (aHR 0.01, 95% CI 0.001–0.10) were independently associated with lower mortality than non-transplant management. Male sex and combined immunodeficiency were independently associated with increased mortality. These findings demonstrate marked heterogeneity in outcomes across pediatric IEI and support earlier diagnosis, expanded molecular testing, timely referral, and greater access to HSCT to improve survival in resource-constrained settings.

  • Open Access

    Efficacy and safety of xyloglucan nasal spray in children with allergic rhinitis: A randomized, double-blind, placebo-controlled, crossover study

    by Piyapong Laopakorn, Potjanee Kiewngam, Wanlapa Jotikasthira, Adithep Sawatchai, Wacharoot Kanchongkittiphon, Wiparat Manuyakorn

    Background: A tamarind seed extract-based solution containing xyloglucan forms a protective layer over the nasal epithelium. However, there is no previous study evaluating xyloglucan efficacy in children with allergic rhinitis (AR). Objective: To evaluate the safety and efficacy of xyloglucan as an adjunctive treatment for AR in children. Methods: This randomized, double-blind, placebo-controlled crossover study assessed the efficacy of xyloglucan nasal spray in managing AR symptoms in children. Participants 6–18 years with AR were randomized to receive either xyloglucan or placebo in addition to their current AR therapy for 2 weeks, followed by a 2-week washout and crossover to the alternate treatment for 2 weeks. Primary outcomes were changes in visual analog scale scores analyzed using linear mixed models, adjusting for treatment, period, sequence, and compliance. Subgroup analyses included children with moderate symptoms and good compliance. Results: Seventy-nine children with AR were enrolled, median age 10 years (IQR: 8–12). Treatment with xyloglucan was associated with a significantly greater reduction in nasal congestion compared to placebo (β = −1.013, 95% confidence interval [CI], −1.729 to −0.298, P = 0.006). In children with moderate symptoms and good compliance, the effect on nasal congestion was more pronounced (β = −1.588, P = 0.046). Improvements in rhinorrhea, sneezing, and itching were observed but did not reach statistical significance. Both treatments were well tolerated, with only mild adverse events in both groups. Conclusion: Xyloglucan nasal spray, as an adjunct to standard AR treatment, demonstrated potential benefits in alleviating rhinitis symptoms, particularly nasal congestion, in children with AR. This clinical trial was registered with the Thai Clinical Trials Registry (No. TCTR20240318004).

  • Impact of age and allergen type on sensitization changes in children with chronic rhinitis

    by Sucheera Nokkaew, Wanlapa Jotikasthira, Potjanee Kiewngam, Adithep Sawatchai, Watcharoot Kanchongkittiphon, Wiparat Manuyakorn


  • Safety of direct oral provocation in children with mild beta‐lactam hypersensitivity reactions

    by Chayaniss Pachasidchai, Yiwa Suksawat, Pailin Yooma, Potjanee Kiewngam, Wanlapa Jotikasthira, Adithep Sawatchai, Natchanun Klangkalya, Watcharoot Kanchongkittiphon, Wiparat Manuyakorn


  • Improvement of inattentive and hyperactive symptoms after real-life rhinitis treatment in school-aged children

    by Chatsuda Thamrongsak, Vilawan Chirdkiatgumchai, Wanlapa Jotikasthira, Potjanee Kiewngam, Watcharoot Kanchongkittiphon, Wiparat Manuyakorn


  • Open Access

    Spatial Estimation of PM2.5 Exposure and its Association with Asthma Exacerbation: A Prospective Study in Thai Children

    by Kornnasa Chankaew, Ratchaneewan Sinitkul, Wiparat Manuyakorn, Koonkoaw Roekworachai, Harutai Kamalaporn

    The acceptable fine particulate matter (PM2.5) level in Thailand is double the recommendation of the World Health Organization. It is necessary to have an accurate measure of PM2.5 exposure and its association with health problems in vulnerable groups such as asthma exacerbation in Thai children to urge the Clean Air Act in Thailand, which is currently in the process of revision. To study the association between PM2.5 exposure and asthma exacerbation in children living in Bangkok Metropolitan Region and Chiang Mai Province. A pilot prospective observational study was conducted at the Chest and Allergy clinic at Ramathibodi Hospital, Mahidol University, Bangkok and at the Chest Clinic at Nakornping Hospital, Chiang Mai, Thailand, from June 2020 to February 2021. Children with asthma, aged 5–18 years old, were recruited. Respiratory symptoms, including cough, chest tightness, dyspnea or wheezing, peak expiratory flow rate, and asthma exacerbation, were recorded twice daily by caregivers. Estimated average daily PM2.5 exposure levels were calculated using ArcGIS® at exacerbation day, three days before exacerbation (lag day 3), and 7 days before exacerbation (lag day 7). Regression analysis was applied to examine the association between PM2.5 exposure and asthma exacerbation. Seventy asthmatic patients were enrolled. The median age was 9.7 (IQR 5–18) years old. There were 53 respiratory symptoms, 5 admissions, and 1 intensive care unit admission. Daily PM2.5 levels above 12 mcg/m3 (the US cut-off level for the sensitive group) has higher sensitivity to detect asthma exacerbation compared to Thai cut-off level for the sensitive group (37 mcg/m3) (sensitivity 98.2% vs 32.1%). The average daily PM2.5 level exposure at lag day 3 in the exacerbation vs the non-exacerbation group was 27.5 and 13.6 mcg/m3 (p < 0.01), respectively. The daily PM2.5 level at lag day 3 was also correlated with an acute asthmatic attack (r = 0.62, p < 0.01) with the 0.2 events increasing of asthmatic exacerbation every 10 mcg/m3 of increment of daily PM2.5 level. Our findings suggest that asthmatic children are sensitive to daily PM2.5 levels above 12 mcg/m3. Exposure to high daily PM2.5 levels can lead to asthma exacerbation within three days. Further participant recruitment is needed to emphasize this association and establish the national data.


  • Association of Dyslipidemia and Respiratory Resistance Assessed by the Forced Oscillation Technique in Asthmatic Children

    by Pakvirin Nanakorn Chanachon, Wanlapa Jotikasthira, Potjanee Kiewngam, Adithep Sawatchai, Watcharoot Kanchongkittiphon, Wiparat Manuyakorn

    Purpose This study aimed to evaluate the associations between dyslipidemia and pulmonary function parameters assessed by spirometry and the forced oscillation technique in asthmatic children. Methods Asthmatic children (5–18 years old) had fasting serum lipid profiles including low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) concentrations, and C-reactive protein (CRP) measured. Pulmonary function tests were assessed by spirometry and the forced oscillation technique (FOT). Results One hundred forty-one asthmatic children were enrolled with a mean (SD) age of 11.82 (3.38) years. Eighty-eight (62.4%) children were boys, 64 (45.4%) had dyslipidemia, and 20 (14.2%) were obese. Among the children with dyslipidemia, a high LDL-C concentration (65.6%) was the most common form of dyslipidemia, followed by high TC (57.8%), high TG (35.9%), and low HDL-C concentrations (15.6%). Multivariable analysis showed significant associations between HDL-C concentrations and respiratory resistance at 5 Hz (R5) and respiratory resistance at 20 Hz (R20), and TC concentrations were modestly associated with reactance at 5 Hz (X5), the frequency of resonance (Fres), and the area of reactance (ALX). Asthmatic children who had high LDL-C concentrations had a significantly higher expiratory phase R5, whole breath R20, and expiratory phase R20 than those in children with normal LDL-C concentrations. Conclusion This study suggests an association of blood cholesterol, especially HDL-C and LDL-C, and respiratory resistance measured by the FOT, irrespective of the obesity status. An intervention for improving LDL-C and HDL-C concentrations may be beneficial on lung function parameters in asthmatic children. Clinical Trial Registration: TCTR20200305005; date of registration: 03-04-2020 (retrospectively registered).


  • Open Access

    Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children

    by Tipyapa Rattanamanee, Putthapoom Lumjiaktase, Nanthisa Kemawichanura, Potjanee Kiewnga, Wanlapa Jotikasthira, Wiparat Manuyakorn

    Background: House dust mites (HDM) are the major causative allergen for allergic rhinitis. The sole disease-modifying therapy for allergic rhinitis is allergen immunotherapy (AIT). Rush immunotherapy is the accelerated build-up schedules to reach the target maintenance dose. Objective: To evaluate the kinetic changes of peripheral blood CD4+CD25+FOXP3+ regulatory T cells (Treg) and serum cytokines in children undergoing 2-day modified rush HDM AIT. Methods: Children aged 5-15 years with allergic rhinitis were enrolled for a 2-day modified rush HDM AIT. Peripheral blood CD4+CD25+FOXP3+ Treg, serum interleukin (IL)-4, IL-13, interferon-γ, and IL-10 were measured at baseline, finishing rush, achieving maintenance dose, 6 months, and 12 months after reaching maintenance dose. Specific IgE (sIgE) to HDM was evaluated at baseline and 12 months after getting the maintenance dose. Rhinitis symptoms were assessed daily using a daily card. Results: A total of 12 children with a mean age of 13 years were enrolled. Rhinitis symptom-free days per month increased significantly after reaching the maintenance dose compared to baseline (from 9.5 days to 19.5 days, p = 0.002), and the maximum improvement was seen at 1 year. The levels of Treg were significantly increased at 6 months after maintenance dose compared to baseline level (6.27%±1.63% vs. 3.83%±1.80%, p < 0.001). After treatment, there were significantly decreased serum IL-13 at 1 year after maintenance but no significant changes in sIgE to HDM. The systemic reaction during AIT occurred 7 episodes from 119 shots (5.9%). Conclusion: Two-day modified rush HDM AIT provides acceptable systemic reactions and increases the number of CD4+CD25+FOXP3+ Treg in children.


  • Open Access

    Efficacy of a newly developed cartoon video on dry powder inhaler technique: a multicenter study

    by Thitima Sirimontakan, Wiparat Manuyakorn, Harutai Kamalaporn, Pornchai Wattanarungsun, Kuntalee Chonpaisan, Korakot Thongkum, Prapasiri Singvijarn, Sintra Phumethum

    One of the factors associated with uncontrolled pediatric asthma is inadequate delivery of inhaled medication to the lungs. Incorrect inhaler technique has been reported. We developed a 2-minute cartoon video instruction aiming to improve dry powder inhaler (DPI) technique. To assess the efficacy of video instruction in improvement of DPI technique in Thai children with asthma. The prospective multicenter cohort study was conducted during March 2018 - February 2019. Children with asthma aged 6-15 years were recruited from the outpatient departments. Five videotapes demonstrated how the patients use DPI devices were recorded as the followings: before and after watching video (V₁pre and V₁post), at one-month (V₂post), at three-month (V₃post) after watching the video and at 5-month follow-up without watching the video (V₄pre). Scoring of correct DPI steps were evaluated by two independent respiratory specialists. Of 57 patients recruited, 30 used Accuhaler™ while 27 used Easyhaler™. In Accuhaler™ group, the median age (range) of 10 (8, 11) year. The mean score of V₁pre, V₁post, V₂post and V₃post were 10.7, 12.3, 12.4, and 12.2 out of 14 respectively. In Easyhaler™ group, the median age (range) of 11 (9-12) year. The mean score of V₁pre, V₁post, V₂post and V₃post were 8.6, 10.4, 11.2 and 11.4 out of 12 respectively. At the five-month follow-up, without watching video, the V₄pre score was still as high as 12.9 ± 1.3 in Accuhaler™ and 11.8 ± 0.4 in Easyhaler™. Our video instruction could improve Accuhaler± and Easyhaler± technique among Thai children with asthma.